<DOC>
	<DOCNO>NCT00908531</DOCNO>
	<brief_summary>The hypothesis address randomized phase III trial 4 month letrozole may superior surgery primary therapy early stage hormone receptor positive breast cancer postmenopausal woman , provide patient receive definitive radical surgery adjuvant therapy otherwise indicate completion preoperative letrozole .</brief_summary>
	<brief_title>Trial Endocrine Against Locoregional Therapy First Postmenopausal Women With Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Informed consent Age 60 year older Measurable nonmetastatic noninflammatory breast cancer Tumor 2 cm large ER and/or PgR positive tumor Comorbidity index 0 3 , e.g. , serious medical condition Prior medical therapy malignant disease , include aromatase inhibitor Distant metastasis Need chemotherapy Past current history neoplasm ( except curative treat basal skin cancer situ carcinoma cervix uterus ) Treatment nonapproved drug within 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast neoplasm</keyword>
	<keyword>Randomised trial</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>Preoperative care</keyword>
	<keyword>Age 60 older</keyword>
	<keyword>Hormone receptor positive tumor</keyword>
	<keyword>Tumor lager 2 cm</keyword>
	<keyword>No distant metastasis</keyword>
</DOC>